671 related articles for article (PubMed ID: 28527946)
1. The microbiome and hepatobiliary-pancreatic cancers.
Mima K; Nakagawa S; Sawayama H; Ishimoto T; Imai K; Iwatsuki M; Hashimoto D; Baba Y; Yamashita YI; Yoshida N; Chikamoto A; Baba H
Cancer Lett; 2017 Aug; 402():9-15. PubMed ID: 28527946
[TBL] [Abstract][Full Text] [Related]
2. The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms.
Mima K; Ogino S; Nakagawa S; Sawayama H; Kinoshita K; Krashima R; Ishimoto T; Imai K; Iwatsuki M; Hashimoto D; Baba Y; Sakamoto Y; Yamashita YI; Yoshida N; Chikamoto A; Ishiko T; Baba H
Surg Oncol; 2017 Dec; 26(4):368-376. PubMed ID: 29113654
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
[TBL] [Abstract][Full Text] [Related]
4. The Role of the Microbiome in Immunologic Development and its Implication For Pancreatic Cancer Immunotherapy.
Sethi V; Vitiello GA; Saxena D; Miller G; Dudeja V
Gastroenterology; 2019 May; 156(7):2097-2115.e2. PubMed ID: 30768986
[TBL] [Abstract][Full Text] [Related]
5. The potential of gut microbiome as a non-invasive predictive biomarker for early detection of pancreatic cancer and hepatocellular carcinoma.
Kaźmierczak-Siedlecka K; Stachowska E; Folwarski M; Przewłócka K; Makarewicz W; Bryl E
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7275-7284. PubMed ID: 34919227
[TBL] [Abstract][Full Text] [Related]
6. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
Jiang JW; Chen XH; Ren Z; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
[TBL] [Abstract][Full Text] [Related]
7. Microbiota Alterations and Their Association with Oncogenomic Changes in Pancreatic Cancer Patients.
Sammallahti H; Kokkola A; Rezasoltani S; Ghanbari R; Asadzadeh Aghdaei H; Knuutila S; Puolakkainen P; Sarhadi VK
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884776
[TBL] [Abstract][Full Text] [Related]
8. Is irreversible electroporation safe and effective in the treatment of hepatobiliary and pancreatic cancers?
Wu LM; Zhang LL; Chen XH; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Apr; 18(2):117-124. PubMed ID: 30655073
[TBL] [Abstract][Full Text] [Related]
9. Harnessing the Microbiome for Pancreatic Cancer Immunotherapy.
Vitiello GA; Cohen DJ; Miller G
Trends Cancer; 2019 Nov; 5(11):670-676. PubMed ID: 31735286
[TBL] [Abstract][Full Text] [Related]
10. Cancers of the large bowel and hepatobiliary tract.
Treat J; Woolley PV
Cancer Chemother Biol Response Modif; 1991; 12():469-89. PubMed ID: 1657090
[No Abstract] [Full Text] [Related]
11. Microbiota dysbiosis: a new piece in the understanding of the carcinogenesis puzzle.
García-Castillo V; Sanhueza E; McNerney E; Onate SA; García A
J Med Microbiol; 2016 Dec; 65(12):1347-1362. PubMed ID: 27902422
[TBL] [Abstract][Full Text] [Related]
12. Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.
Onesti CE; Romiti A; Roberto M; Falcone R; Marchetti P
Expert Rev Anticancer Ther; 2015; 15(10):1183-98. PubMed ID: 26325474
[TBL] [Abstract][Full Text] [Related]
13. Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response.
Sethi V; Kurtom S; Tarique M; Lavania S; Malchiodi Z; Hellmund L; Zhang L; Sharma U; Giri B; Garg B; Ferrantella A; Vickers SM; Banerjee S; Dawra R; Roy S; Ramakrishnan S; Saluja A; Dudeja V
Gastroenterology; 2018 Jul; 155(1):33-37.e6. PubMed ID: 29630898
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virotherapy in hepato-bilio-pancreatic cancer: The key to breaking the log jam?
Li Y; Shen Y; Zhao R; Samudio I; Jia W; Bai X; Liang T
Cancer Med; 2020 May; 9(9):2943-2959. PubMed ID: 32130786
[TBL] [Abstract][Full Text] [Related]
15. The Unique Microbiome and Immunity in Pancreatic Cancer.
Wei X; Mei C; Li X; Xie Y
Pancreas; 2021 Feb; 50(2):119-129. PubMed ID: 33565788
[TBL] [Abstract][Full Text] [Related]
16. Cancers of the pancreas and hepatobiliary system.
Sauerland C; Engelking C; Wickham R; Pearlstone DB
Semin Oncol Nurs; 2009 Feb; 25(1):76-92. PubMed ID: 19217507
[TBL] [Abstract][Full Text] [Related]
17. Problems in staging of pancreatic and hepatobiliary tumours.
Schmied BM; Z'graggen K; Redaelli CA; Büchler MW
Ann Oncol; 2000; 11 Suppl 3():161-4. PubMed ID: 11079134
[No Abstract] [Full Text] [Related]
18. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota and mTOR signaling: Insight on a new pathophysiological interaction.
Noureldein MH; Eid AA
Microb Pathog; 2018 May; 118():98-104. PubMed ID: 29548696
[TBL] [Abstract][Full Text] [Related]
20. [Liver, Pancreas, Biliary Tract Cancer Current Issues of Surgical Margin, R0 and R1, in Surgical Resection for Hepatobiliary Pancreatic Cancer].
Miyazaki M
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1415-1416. PubMed ID: 30382035
[No Abstract] [Full Text] [Related]
[Next] [New Search]
